SEC Form 4 · accession 0001179110-18-009834
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vickesh Myer
Officer — Chief Technology Officer
Period of report
Jul 17, 2018
Accepted (ET)
Jul 19, 2018 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 17, 2018 | M | 3,000 | $0.65 | A | 3,000 | D | |
| Common Stock | Jul 17, 2018 | S | 3,000 | $34.66 | D | 0 | D | |
| Common Stock | Jul 17, 2018 | M | 4,000 | $0.65 | A | 4,000 | D | |
| Common Stock | Jul 17, 2018 | S | 4,000 | $36.50 | D | 0 | D | |
| Common Stock | Jul 18, 2018 | M | 6,150 | $11.21 | A | 6,150 | D | |
| Common StockF2 | Jul 18, 2018 | S | 6,150 | $35.46 | D | 0 | D | |
| Common Stock | Jul 18, 2018 | M | 850 | $11.21 | A | 850 | D | |
| Common StockF3 | Jul 18, 2018 | S | 850 | $36.25 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $0.65 | Jul 17, 2018 | M | 7,000 | D | — | Apr 29, 2025 | Common Stock | 7,000 | 97,307 | D |
| Stock Option (right to buy)F5 | $11.21 | Jul 18, 2018 | M | 7,000 | D | — | Oct 29, 2025 | Common Stock | 7,000 | 76,897 | D |
Explanation of responses
- F1The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $35.11 to $36.10. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $36.12 to $36.45. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This option was granted on April 30, 2015 and is scheduled to vest over four years with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.
- F5This option was granted on October 30, 2015 and is scheduled to vest over four years with 25% of the shares having vested on October 27, 2016, and the remaining 75% of the shares schedule to vest in equal monthly installments thereafter through October 27, 2019.